Population-Based Trends in Prevalence of Nonalcoholic Fatty Liver Disease in US Adults With Type 2 Diabetes
- PMID: 30458246
- DOI: 10.1016/j.cgh.2018.11.023
Population-Based Trends in Prevalence of Nonalcoholic Fatty Liver Disease in US Adults With Type 2 Diabetes
Abstract
Type 2 diabetes (T2D) affects more than 9% of U.S. adults.1 Nonalcoholic fatty liver disease (NAFLD) has been recognized as a common co-morbidity in T2D. However, most previous epidemiologic studies have been subject to ascertainment and selection bias or had small sample sizes. No recent studies have examined trends of the burden of NAFLD in diabetic patients. Using noninvasive scores and the National Health and Nutrition Examination Survey (NHANES), we aimed to estimate the population-based trends in prevalence of NAFLD-associated comorbidities in U.S. adults with T2D.
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Trends in pioglitazone use among U.S. adults with type 2 diabetes and suspected nonalcoholic fatty liver disease.Expert Opin Investig Drugs. 2020 Feb;29(2):205-208. doi: 10.1080/13543784.2020.1704731. Epub 2019 Dec 24. Expert Opin Investig Drugs. 2020. PMID: 31829750
-
Overall and subgroup prevalence of non-alcoholic fatty liver disease and prevalence of advanced fibrosis in the United States: An updated national estimate in National Health and Nutrition Examination Survey (NHANES) 2011-2018.Ann Hepatol. 2024 Jan-Feb;29(1):101154. doi: 10.1016/j.aohep.2023.101154. Epub 2023 Sep 22. Ann Hepatol. 2024. PMID: 37742743
-
Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.Am J Gastroenterol. 2017 Apr;112(4):581-587. doi: 10.1038/ajg.2017.5. Epub 2017 Feb 14. Am J Gastroenterol. 2017. PMID: 28195177
-
Nonalcoholic Fatty Liver Disease and Diabetes: An Epidemiological Perspective.Endocrinol Metab (Seoul). 2019 Sep;34(3):226-233. doi: 10.3803/EnM.2019.34.3.226. Endocrinol Metab (Seoul). 2019. PMID: 31565874 Free PMC article. Review.
-
Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis.Diabetes Metab J. 2019 Feb;43(1):31-45. doi: 10.4093/dmj.2019.0011. Diabetes Metab J. 2019. PMID: 30793550 Free PMC article. Review.
Cited by
-
Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes.Hepatology. 2020 Oct;72(4):1242-1252. doi: 10.1002/hep.31157. Hepatology. 2020. PMID: 32022277 Free PMC article.
-
Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease.Aliment Pharmacol Ther. 2024 Jun;59 Suppl 1(Suppl 1):S41-S51. doi: 10.1111/apt.17752. Aliment Pharmacol Ther. 2024. PMID: 38813822 Free PMC article. Review.
-
Risk factors in nonalcoholic fatty liver disease.Clin Mol Hepatol. 2023 Feb;29(Suppl):S79-S85. doi: 10.3350/cmh.2022.0398. Epub 2022 Dec 14. Clin Mol Hepatol. 2023. PMID: 36517003 Free PMC article. Review.
-
Association of concomitant MASLD and hepatitis B virus with clinical prognosis in hepatocellular carcinoma after curative resection.Am J Cancer Res. 2025 Feb 15;15(2):737-748. doi: 10.62347/KSLN5850. eCollection 2025. Am J Cancer Res. 2025. PMID: 40084366 Free PMC article.
-
Non‑high‑density lipoprotein cholesterol to high‑density lipoprotein cholesterol ratio as a biomarker for liver health: Insights from National Health and Nutrition Examination Survey data.Biomed Rep. 2025 Feb 7;22(4):61. doi: 10.3892/br.2025.1939. eCollection 2025 Apr. Biomed Rep. 2025. PMID: 39990999 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical